FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
December 20, 2021 08:00 ET
|
FibroGen, Inc.
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...
FibroGen to Present at Upcoming Investor Conferences
November 02, 2021 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following...
FibroGen to Report Third Quarter 2021 Financial Results
October 26, 2021 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will...
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
October 25, 2021 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American...
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET
|
FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
June 11, 2021 09:40 ET
|
The Rosen Law Firm PA
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017...
FGEN BREAKING NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
June 05, 2021 15:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
May 27, 2021 14:58 ET
|
The Rosen Law Firm PA
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and...
FibroGen to Present at Upcoming Investor Conferences
May 27, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm
May 26, 2021 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...